MBNL1 and myotonic dystrophy type 1: The approaches focused on the removal of mutant DMPK mRNA and correction of two major RNA-binding proteins, CUGBP1 and MBNL1, involved in DM1, or their critical downstream targets are tested in the clinical studies; therefore, they might be closer to the transition to clinic (Figure 2B–E).